1. Trial at a Glance
STOP-NIDDM was a randomized, parallel, quadruple-masked phase 3 trial evaluating acarbose compared with placebo in participants with metabolic syndrome.
| Feature | STOP-NIDDM |
|---|---|
| Condition | Metabolic Syndrome |
| Design | Randomized, parallel |
| Allocation | Randomized |
| Enrollment | 1429 |
| Interventions | Acarbose (drug); placebo (drug) |
| Primary endpoint | Incidence of newly diagnosed type 2 diabetes |
| Sponsor | GWT-TUD GmbH |
2. Clinical Question
The primary statistical question was whether acarbose changed the incidence of newly diagnosed type 2 diabetes compared with placebo in the trial population.
Population
Participants enrolled in the STOP-NIDDM trial with metabolic syndrome.
Intervention
Acarbose.
Comparator
Placebo.
Primary question
What was the effect of randomized acarbose assignment on incidence of newly diagnosed type 2 diabetes?
3. Trial Design
Randomization
1429 participants
Two arms
Acarbose vs placebo
Follow-up
Primary endpoint assessment
Analysis
Endpoint comparison
Acarbose arm
Randomized intervention arm receiving acarbose.
Placebo arm
Randomized comparator arm receiving placebo.
4. Endpoints
| Endpoint | Definition |
|---|---|
| Primary endpoint | Incidence of newly diagnosed type 2 diabetes |
5. Planned Analysis
The registry identifies the primary endpoint as incidence of newly diagnosed type 2 diabetes. For an endpoint measuring occurrence of a new diagnosis over follow-up, statistical analysis would typically compare the cumulative incidence between randomized groups using methods appropriate for binary or time-to-event outcomes depending on the prespecified statistical analysis plan.
6. Statistical Methodology
Randomized comparison
Randomization is designed to balance known and unknown baseline factors between treatment groups. This allows differences observed after randomization to be interpreted within the framework of the assigned intervention comparison.
Incidence endpoints
Incidence of a newly diagnosed condition is a measure of event occurrence in a defined population over follow-up. Analysis generally focuses on whether the frequency or timing of events differs between randomized groups.
Masking
The trial used quadruple masking, which reduces the potential influence of treatment knowledge on participants, investigators, outcome assessment, and other trial processes.
7. Statistical Methods Explained
Why does randomization matter?
Randomization creates comparable groups at baseline and is the foundation for estimating the effect of the assigned intervention.
What does an incidence endpoint measure?
It measures the occurrence of newly diagnosed type 2 diabetes rather than only characteristics observed at enrollment.
Why is masking important?
Masking helps limit differences in behavior, assessment, or reporting caused by awareness of treatment assignment.
Why are statistical methods prespecified?
A prespecified analysis plan defines how outcomes will be compared before results are known, helping preserve the validity of inference.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or numerical outcome results.
- Effect estimates, confidence intervals, and p-values cannot be described from the registry information available.
- Interpretation of the primary endpoint depends on the detailed statistical analysis plan and endpoint definitions.
9. Why This Trial Matters Statistically
| Concept | How it appears in STOP-NIDDM |
|---|---|
| Randomization | Randomized two-arm comparison |
| Masking | Quadruple-masked design |
| Clinical endpoint | Incidence of newly diagnosed type 2 diabetes |
| Comparative inference | Acarbose versus placebo evaluation |